Maximus Review

Maximus is a telehealth hormone-optimization platform for men, built around named protocols rather than an open-ended clinical relationship. The one it is known for uses enclomiphene, a testosterone-raising treatment that works through the body's own production pathway instead of replacing testosterone from outside. Among telehealth TRT platforms, offering enclomiphene as a standard protocol option is uncommon.

Scope is narrow by design. Maximus measures hormones and the safety markers a hormone protocol requires. It does not measure ApoB, Lp(a), fasting insulin, or the nutrient and inflammation set that a general longevity program covers, and it does not treat outside hormones. Judge it on the hormone question, not on breadth it does not claim.

Scorecard

What you get for the money

Maximus sells protocols. You pay a monthly figure attached to a named treatment, and what arrives is the medication plus the clinical oversight that medication requires. The structure is simpler than a membership and less flexible than an a la carte program.

• Bundled — the medication. Enclomiphene, testosterone, or a combination, shipped on a recurring cadence from a partner pharmacy.
• Bundled — clinician oversight. A prescriber reviews your baseline, writes the protocol, and adjusts the dose as follow-up labs come in.
• Bundled — protocol support. Instructions, supplies where the protocol needs them, and a channel to report side effects between checks.
• Typically separate — the initial assessment and baseline labs. These are usually billed outside the monthly figure, which is the most common source of a surprise on the first bill.
• Typically separate — follow-up labs. Titration and maintenance draws are priced by market and are not inside the protocol fee.
• Not offered — general biomarker work. Lipids, inflammation, nutrients, and metabolic markers sit outside the product.
• Not offered — peptides and GLP-1 medications. These require a different provider.

What it costs

The monthly band is $150 to $300+, and where you land inside it depends on the protocol rather than on a tier you choose. The figure that actually matters is year one including the assessment and labs, because those are quoted separately and are easy to leave out of a mental estimate.

Two things push the number toward the top of the band. Adding an ancillary medication to a base protocol is the first. Frequent lab work during a titration is the second, and labs are the line item people underestimate most — a full hormone panel run twice in the first year is a meaningful addition to a $150/mo protocol. Ask for the lab cost in writing before starting, and ask whether the panel can be run through your own insurance instead.

Signing up and the first visit

Intake is a questionnaire covering symptoms, medical history, current medications, and — importantly for protocol selection — whether you intend to father children. That last answer is the fork in the road between the enclomiphene pathway and a conventional testosterone pathway, so answer it with a ten-year horizon rather than a current one.

Baseline blood work follows, and it is a venous draw at a lab rather than an at-home finger-prick. Fasting is typically required and the draw should be scheduled for the morning, because testosterone follows a diurnal curve and an afternoon sample can read materially lower than the same person tested at 8am. Results generally post within about a week of the draw.

A clinician then reviews the baseline and either writes a protocol or explains why one is not appropriate. Where a controlled substance is involved, state law determines whether the consult must be a live video visit. Enclomiphene is not a controlled substance, which is one reason its pathway can move faster in some states than a testosterone pathway. Medication ships from a partner pharmacy after the prescription is written. From first order to first dose, most people are looking at three to five weeks.

What the panel covers

The baseline panel exists to answer two questions: is testosterone genuinely low, and which mechanism is responsible. The named groups:

• Androgens. Total and free testosterone. Free testosterone is the more informative figure when SHBG is abnormal, which it often is in men who are lean and highly trained, or in men with fatty liver.
• Pituitary signalling. LH and FSH. These are the markers the whole protocol decision turns on, because they distinguish a testicular failure from a central signalling problem.
• Binding and conversion. SHBG and estradiol. Enclomiphene raises testosterone and estradiol together, so an estradiol baseline is needed to interpret what happens next.
• Safety markers. Hematocrit and hemoglobin via CBC, plus PSA. Both are required before any testosterone-raising therapy and both are re-checked on protocol.
• Basic metabolic and liver function. Enough to catch a confounder or a contraindication, not enough to constitute a metabolic workup.

The eligibility logic is worth stating plainly, because it determines whether the product works for you at all. Enclomiphene raises testosterone by increasing LH and FSH output. If LH is already elevated at baseline, the pituitary is signalling as hard as it can and the testes are not responding — that is primary hypogonadism, and pushing the signal harder produces little. If LH is low or mid-range with low testosterone, the signalling pathway is intact and enclomiphene has something to act on. That single measurement, not symptom severity, is what should select the protocol.

Strengths

• Enclomiphene is offered as a standard protocol rather than a special request, which is uncommon among telehealth TRT platforms and is the reason most people arrive here.
• Fertility is preserved. LH and FSH stay intact, so sperm production and testicular volume are maintained in a way conventional TRT does not maintain them.
• Stopping is cleaner. Enclomiphene does not create the suppressed-axis recovery period that discontinuing exogenous testosterone does, which lowers the cost of changing your mind.
• The protocol is oral and daily, with no injections, no needles, and no topical transfer risk to a partner or child.
• Enclomiphene is not a controlled substance, which simplifies prescribing and refills in states with strict telehealth rules around Schedule III medications.
• The named-protocol structure makes the offer legible. You can see what you are buying before signing up, rather than discovering the plan after an intake call.

Trade-offs

• Panel breadth is narrow. Lipids beyond the basics, inflammation, nutrients, and metabolic markers are not covered, so those risks go unmeasured during treatment.
• Labs and the initial assessment are typically billed separately, so the monthly figure understates the real annual cost by a meaningful margin.
• Enclomiphene does not work in primary hypogonadism, where LH is already high. That eligibility limit rules out a real share of men with low testosterone.
• Estradiol rises alongside testosterone on this mechanism, and some men get breast tenderness or mood effects that need dose adjustment or a protocol change.
• Long-term safety data on enclomiphene is thinner than for testosterone therapy, which has decades of use behind it. The mechanism is well understood; the multi-decade outcome data is not there.
• No peptide, GLP-1, thyroid, or metabolic pathway. A finding outside hormones means finding a second provider.

How it compares

The four programs below are the closest comparison set — telehealth-first, hormone-treating, sold as a recurring relationship. They are listed alphabetically, and the same six criteria are applied to every row.

Read the last two columns together. Maximus and Marek Health both build fertility-preserving protocols as a normal part of the offer, but they get there differently: Maximus through a standardized named protocol at $150–$300+/mo, Marek Health through a per-client build with much deeper lab work and a year-one range of $2,500–$6,000+. Hone Health has the cheapest and fastest entry at ~$45 for an at-home finger-prick test, with hCG or enclomiphene available on request rather than as the headline pathway. Lifeforce carries the broadest routine panel of the four at ~40 markers and bundles the clinician consult into ~$129/mo, but hormones are one part of its scope rather than the whole of it.

Who should buy it — and who should not

Buy it if:

• You want higher testosterone and intend to father children, now or within the next several years.
• Your baseline LH is low or mid-range with low testosterone, meaning the signalling pathway is intact and enclomiphene has something to act on.
• You want the option to stop treatment without a suppressed-axis recovery period.
• You prefer a daily oral medication over weekly injections or daily topical application.
• You want a clearly-defined protocol with a stated monthly price rather than an open-ended clinical engagement.

Look elsewhere if:

• You want conventional TRT with no fertility concern and the lowest entry cost — Hone Health starts at ~$45 for the test.
• You want hormones plus a broader panel and a bundled clinician — Lifeforce covers ~40 markers at ~$129/mo after the entry month.
• You want deep, frequent lab work through a titration — Marek Health retests every 8–12 weeks on a buyer-selected panel.
• You want a general longevity biomarker picture rather than hormone treatment — Function Health and Superpower cover 100+ markers at $499/yr.
• Your question spans hormones, metabolic health, and inflammation under one physician — compare the full set of doctor-led options.

A named exception: men with a history of visual disturbance on a SERM, or with an untreated thyroid disorder driving the symptoms, should resolve that before starting. And if prolactin is elevated at baseline, the correct next step is a prolactin workup rather than a hormone protocol of any kind — a prolactinoma produces exactly the low-LH, low-testosterone pattern that otherwise looks like an ideal enclomiphene candidate.

Retesting and what year two costs

The first follow-up lands at 6–12 weeks after starting. It checks whether testosterone actually moved, how far estradiol came up with it, and whether hematocrit is drifting. On an enclomiphene protocol the LH response is the marker that confirms the mechanism is working as intended — if LH did not rise, the dose or the protocol is wrong. After that, maintenance labs settle into a six- to twelve-month rhythm.

Year two drops the initial assessment and generally runs one or two lab rounds instead of two or three. Twelve months of protocol at $150–$300+ plus maintenance labs puts the realistic figure around $1,800–$3,600. The renewal buys the medication and the oversight — the same scope as year one, with no additional markers and no widening of the panel.

Worth planning for: a hormone protocol is a multi-year commitment whichever mechanism you choose, and the useful comparison across platforms is five years of total cost, not the first month. At the mid-point of the band, five years on Maximus runs roughly $11,000–$18,000 including labs. That figure is the one to weigh against the alternatives, and against what a general practitioner would charge to manage the same protocol if one in your area will.

Related

• All doctor-led options compared
• Hone Health review
• Lifeforce review
• Marek Health review
• Marek Health vs Maximus
• Opt Health vs Maximus
• Maximus cost breakdown
• Maximus alternatives — six TRT options compared
• Is Maximus worth it?
• Best TRT clinics
• SHBG — what it does and why it changes your free testosterone